Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US44486Q1031
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG00XPPT7S7
HUMA
Humacyte Inc
GICS: Financials · SECTOR: EQTY · SUB-SECTOR: - · THEMEFOLIO: $BANK
NAME
Humacyte Inc
ISIN
US44486Q1031
TICKER
HUMA
MIC
XNAS
REUTERS
HUMA.OQ
BLOOMBERG
HUMA US
Do., 12.12.2024       Humacyte
US44486Q1031

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Humacyte To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in Humacyte between May 10, 2024 and October 17, 2024 and would like to discuss your legal rights, call Faruqi &...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Do., 12.12.2024       Humacyte
US44486Q1031

NEW YORK, Dec. 12, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Humacyte, Inc. (NASDAQ: HUMA). Shareholders who purchased shares of HUMA during the class period listed are encouraged to con...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Do., 12.12.2024       Humacyte
US44486Q1031

New York, New York--(Newsfile Corp. - December 11, 2024) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Humacyte, Inc. (NASDAQ: HUMA) between May 10, 2024 and October 17, 2024, both dates inclusive (the "Class Period"), of the important January 17, 2025 lead plaintiff deadline.SO WHAT: If you purc...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Do., 12.12.2024       Humacyte
US44486Q1031

BENSALEM, Pa., Dec. 11, 2024 /PRNewswire/ -- Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Humacyte, Inc. ("Humacyte" or the "Company") (NASDAQ: HUMA). Class Period: May 10, 2024 – October 17, 2024Lead Plaintiff Deadline: January 17, 2025...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Mi., 11.12.2024       Humacyte
US44486Q1031

HUMA Investors with Losses Encouraged to Contact the FirmSan Francisco, California--(Newsfile Corp. - December 11, 2024) - Humacyte, a biotechnology company focused on regenerative medicine, is now facing an investor class action alleging that the company misled investors about the status of its key product and the regulatory compliance of its manu...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Mi., 11.12.2024       Humacyte
US44486Q1031

LOS ANGELES, Dec. 11, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humacyte, Inc. ("Humacyte" or "the Company") (NASDAQ: HUMA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S....
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Mi., 11.12.2024       Humacyte
US44486Q1031

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Humacyte To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $75,000 in Humacyte between May 10, 2024 and October 17, 2024 and would like to discuss your legal rights, call Faruqi & Fa...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Di., 10.12.2024       Humacyte
US44486Q1031

New York, New York--(Newsfile Corp. - December 10, 2024) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Humacyte, Inc. (NASDAQ: HUMA) between May 10, 2024 and October 17, 2024, both dates inclusive (the "Class Period"), of the important January 17, 2025 lead plaintiff deadline.SO WHAT: If you purc...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Di., 10.12.2024       Humacyte
US44486Q1031

SAN DIEGO, Dec. 10, 2024 /PRNewswire/ -- Robbins LLP reminds investors of the class action filed on behalf of all persons and entities that purchased or otherwise acquired Humacyte, Inc. (NASDAQ: HUMA) securities between May 10, 2024 and October 17, 2024. Humacyte and its consolidated subsidiaries develop and manufacture off-the-shelf, implantabl...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Di., 10.12.2024       Humacyte
US44486Q1031

NEW YORK, Dec. 10, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Humacyte, Inc. ("Humacyte, Inc." or the "Company") (NASDAQ: HUMA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Di., 10.12.2024       Humacyte
US44486Q1031

NEW YORK, Dec. 9, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Humacyte, Inc. ("Humacyte" or the "Company") (NASDAQ: HUMA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encou...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Mo., 09.12.2024       Humacyte
US44486Q1031

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Humacyte To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $75,000 in Humacyte between May 10, 2024 and October 17, 2024 and would like to discuss your legal rights, call Faruqi &...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Mo., 09.12.2024       Humacyte
US44486Q1031

NEW YORK, Dec. 9, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Humacyte, Inc. (NASDAQ: HUMA). Shareholders who purchased shares of HUMA during the class period listed are encouraged to cont...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Mo., 09.12.2024       Humacyte
US44486Q1031

New York, New York--(Newsfile Corp. - December 8, 2024) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Humacyte, Inc. (NASDAQ: HUMA) between May 10, 2024 and October 17, 2024, both dates inclusive (the "Class Period"), of the important January 17, 2025 lead plaintiff deadline.SO WHAT: If you purch...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Sa., 07.12.2024       Humacyte
US44486Q1031

New York, New York--(Newsfile Corp. - December 7, 2024) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Humacyte, Inc. (NASDAQ: HUMA) between May 10, 2024 and October 17, 2024, both dates inclusive (the "Class Period"), of the important January 17, 2025 lead plaintiff deadline.SO WHAT: If you purchased...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Fr., 06.12.2024       Humacyte
US44486Q1031

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Humacyte To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $75,000 in Humacyte between May 10, 2024 and October 17, 2024 and would like to discuss your legal rights, call Faruqi &...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Fr., 06.12.2024       Humacyte
US44486Q1031

NEW YORK, Dec. 6, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Humacyte, Inc. (NASDAQ: HUMA) between May 10, 2024 and October 17, 2024, both dates inclusive (the "Class Period"), of the important January 17, 2025 lead plaintiff deadline....
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Fr., 06.12.2024       Humacyte
US44486Q1031

San Francisco, California--(Newsfile Corp. - December 6, 2024) - Humacyte, a biotechnology company focused on regenerative medicine, is now facing an investor class action alleging that the company misled investors about the status of its key product and the regulatory compliance of its manufacturing facilities.Hagens Berman urges investors in Huma...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Fr., 06.12.2024       Humacyte
US44486Q1031

New York, New York--(Newsfile Corp. - December 5, 2024) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Humacyte, Inc. (NASDAQ: HUMA) between May 10, 2024 and October 17, 2024, both dates inclusive (the "Class Period"), of the important January 17, 2025 lead plaintiff deadline.SO WHAT: If you purch...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Do., 05.12.2024       Humacyte
US44486Q1031

LOS ANGELES, Dec. 5, 2024 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Humacyte, Inc. ("Humacyte" or the "Company") (NASDAQ: HUMA)....
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Do., 05.12.2024       Humacyte
US44486Q1031

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Humacyte To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in Humacyte between May 10, 2024 and October 17, 2024 and would like to discuss your legal rights, call Faruqi &...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Do., 05.12.2024       Humacyte
US44486Q1031

NEW YORK, Dec. 5, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Humacyte, Inc. (NASDAQ: HUMA). Shareholders who purchased shares of HUMA during the class period listed are encouraged to cont...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Mi., 04.12.2024       Humacyte
US44486Q1031

New York, New York--(Newsfile Corp. - December 4, 2024) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Humacyte, Inc. (NASDAQ: HUMA) between May 10, 2024 and October 17, 2024, both dates inclusive (the "Class Period"), of the important January 17, 2025 lead plaintiff deadline.SO WHAT: If you purch...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Mi., 04.12.2024       Humacyte
US44486Q1031

HUMA Investors with Losses Encouraged to Contact the FirmSan Francisco, California--(Newsfile Corp. - December 3, 2024) - Humacyte, Inc. (NASDAQ: HUMA) and certain of its executives are now defendants in a class action lawsuit filed in the U.S. District Court for the Middle District of North Carolina. The suit, Cutshall v. Humacyte, Inc., et al., a...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Di., 03.12.2024       Humacyte
US44486Q1031

New York, New York--(Newsfile Corp. - December 3, 2024) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Humacyte, Inc. (NASDAQ: HUMA) between May 10, 2024 and October 17, 2024, both dates inclusive (the "Class Period"), of the important January 17, 2025 lead plaintiff deadline.SO WHAT: If you purch...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Di., 03.12.2024       Humacyte
US44486Q1031

NEW YORK, Dec. 3, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Humacyte, Inc. ("Humacyte" or the "Company") (NASDAQ: HUMA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encou...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Di., 03.12.2024       Humacyte
US44486Q1031

NEW YORK, Dec. 3, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Humacyte, Inc. ("Humacyte, Inc." or the "Company") (NASDAQ: HUMA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to r...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Mo., 02.12.2024       Humacyte
US44486Q1031

The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the North Carolina Middle District on behalf of those who acquired Humacyte, Inc. (“Humacyte” or the “Company”) (NASDAQ: HUMA) securities during the period of May 10, 2024 to October 17, 2024, inclusive (“the Class Period...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Mo., 02.12.2024       Humacyte
US44486Q1031

LOS ANGELES, Dec. 2, 2024 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Humacyte, Inc. ("Humacyte" or the "Company") (NASDAQ: HUMA)....
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Mo., 02.12.2024       Humacyte
US44486Q1031

DURHAM, N.C., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Founder, President, and Chief Executive Officer, will participate in a fireside chat pr...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
So., 01.12.2024       Humacyte
US44486Q1031

Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Humacyte, Inc. (“Humacyte” or “the Company”) (NASDAQ: HUMA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged vio...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
So., 01.12.2024       Humacyte
US44486Q1031

NEW YORK, Dec. 1, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Humacyte, Inc. (NASDAQ: HUMA) between May 10, 2024 and October 17, 2024, both dates inclusive (the "Class Period"), of the important January 17, 2025 lead plaintiff deadline....
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Fr., 29.11.2024       Humacyte
US44486Q1031

NEW YORK, Nov. 29, 2024 /PRNewswire/ -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Humacyte, Inc. ("Humacyte" or "the Company") (NASDAQ: HUMA) and certain of its officers....
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Fr., 29.11.2024       Humacyte
US44486Q1031

New York, New York--(Newsfile Corp. - November 29, 2024) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Humacyte, Inc. (NASDAQ: HUMA) between May 10, 2024 and October 17, 2024, both dates inclusive (the "Class Period"), of the important January 17, 2025 lead plaintiff deadline.SO WHAT: If you purc...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Fr., 29.11.2024       Humacyte
US44486Q1031

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Humacyte To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $75,000 in Humacyte between May 10, 2024 and October 17, 2024 and would like to discuss your legal rights, call Faruqi & Fa...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Fr., 29.11.2024       Humacyte
US44486Q1031

LOS ANGELES, Nov. 29, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humacyte, Inc. ("Humacyte" or "the Company") (NASDAQ: HUMA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S....
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Do., 28.11.2024       Humacyte
US44486Q1031

New York, New York--(Newsfile Corp. - November 28, 2024) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Humacyte, Inc. (NASDAQ: HUMA) between May 10, 2024 and October 17, 2024, both dates inclusive (the "Class Period"), of the important January 17, 2025 lead plaintiff deadline.SO WHAT: If you purc...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Mi., 27.11.2024       Humacyte
US44486Q1031

New York, New York--(Newsfile Corp. - November 27, 2024) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Humacyte, Inc. ("Humacyte" or "the Company") (NASDAQ: HUMA) and certain of its officers.Class DefinitionThis lawsuit seeks to recover damages again...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Mi., 27.11.2024       Humacyte
US44486Q1031

BENSALEM, Pa., Nov. 27, 2024 /PRNewswire/ -- Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Humacyte, Inc. ("Humacyte" or the "Company") (NASDAQ: HUMA). Class Period: May 10, 2024 – October 17, 2024Lead Plaintiff Deadline: January 17, 2025...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Di., 26.11.2024       Humacyte
US44486Q1031

New York, New York--(Newsfile Corp. - November 26, 2024) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Humacyte, Inc. (NASDAQ: HUMA) between May 10, 2024 and October 17, 2024, both dates inclusive (the "Class Period"), of the important January 17, 2025 lead plaintiff deadline.SO WHAT: If you purc...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Di., 26.11.2024       Humacyte
US44486Q1031

NEW YORK, Nov. 26, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Humacyte, Inc. ("Humacyte, Inc." or the "Company") (NASDAQ: HUMA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Di., 26.11.2024       Humacyte
US44486Q1031

NEW YORK, Nov. 25, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Humacyte, Inc. ("Humacyte" or the "Company") (NASDAQ: HUMA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are enco...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Mo., 25.11.2024       Humacyte
US44486Q1031

NEW YORK, Nov. 25, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Humacyte, Inc. (NASDAQ: HUMA) between May 10, 2024 and October 17, 2024, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Mo., 25.11.2024       Humacyte
US44486Q1031

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Humacyte To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $75,000 in Humacyte between May 10, 2024 and October 17, 2024 and would like to discuss your legal rights, call Faruqi &...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Sa., 23.11.2024       Humacyte
US44486Q1031

New York, New York--(Newsfile Corp. - November 23, 2024) - WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Humacyte, Inc. (NASDAQ: HUMA) between May 10, 2024 and October 17, 2024, both dates inclusive (the "Class Period"). A class action lawsuit has...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Fr., 22.11.2024       Humacyte
US44486Q1031

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Humacyte, Inc. (“Humacyte” or “the Company”) (NASDAQ: HUMA) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged viol...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Fr., 22.11.2024       Humacyte
US44486Q1031

New York, New York--(Newsfile Corp. - November 22, 2024) - WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Humacyte, Inc. (NASDAQ: HUMA) between May 10, 2024 and October 17, 2024, both dates inclusive (the "Class Period"). A class action lawsuit has...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Fr., 22.11.2024       Humacyte
US44486Q1031

Law Offices of Howard G. Smith reminds investors of the upcoming January 17, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Humacyte, Inc. (“Humacyte” or the “Company”) (NASDAQ: HUMA) securities between May 10, 2024 and October 17, 2024, inclusive (the “Class Period”). Investors suffering los...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Fr., 22.11.2024       Humacyte
US44486Q1031

San Francisco, California--(Newsfile Corp. - November 22, 2024) - Humacyte, Inc. (NASDAQ: HUMA) and certain of its executives are now defendants in a class action lawsuit filed in the U.S. District Court for the Middle District of North Carolina. The suit, Cutshall v. Humacyte, Inc., et al., alleges that the company misled investors about the statu...
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink
Fr., 22.11.2024       Humacyte
US44486Q1031

LOS ANGELES, Nov. 22, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Humacyte, Inc. ("Humacyte" or "the Company") (NASDAQ: HUMA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S....
Zur Nachricht
Humacyte
Charts & Research Termsheets Terminal
Permalink